proteon™ manager 3.1.0 Search Results


bio rad proteon manager software  (Bio-Rad)
96
Bio-Rad bio rad proteon manager software
Bio Rad Proteon Manager Software, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/ProteOn+Manager+Software/pmc05673489-1069-8-8
Average 96 stars, based on 1 article reviews
bio rad proteon manager software - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
proteon manager version 3 1 0 6  (Bio-Rad)
93
Bio-Rad proteon manager version 3 1 0 6
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Proteon Manager Version 3 1 0 6, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/ProteOn+HTG+Sensor+Chip/pmc07233522-125-9-13
Average 93 stars, based on 1 article reviews
proteon manager version 3 1 0 6 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
r version 3.1.0  (RStudio)
90
RStudio r version 3.1.0
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
R Version 3.1.0, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/rstudio+version+1+3+1093/pm26048558-98-8-17
Average 90 stars, based on 1 article reviews
r version 3.1.0 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
jenoptik bioinstruments  (JENOPTIK Inc)
90
JENOPTIK Inc jenoptik bioinstruments
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Jenoptik Bioinstruments, supplied by JENOPTIK Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/jenoptik+bioinstruments/10__1177_slash_221106829800300609-154-25-18
Average 90 stars, based on 1 article reviews
jenoptik bioinstruments - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
arcgis pro 3.1.0  (Esri inc)
90
Esri inc arcgis pro 3.1.0
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Arcgis Pro 3.1.0, supplied by Esri inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/arcgis+pro+3+0/pm40430781-30-24-24
Average 90 stars, based on 1 article reviews
arcgis pro 3.1.0 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
reemap v. 3.1.0  (Macrofocus GmbH)
90
Macrofocus GmbH reemap v. 3.1.0
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Reemap V. 3.1.0, supplied by Macrofocus GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/reemap+v++3+1+0/pmc04657976__pone__0143566__s002-13-0-33
Average 90 stars, based on 1 article reviews
reemap v. 3.1.0 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
aerosol instrument manager 10.3.1.0  (TSI Incorporated)
90
TSI Incorporated aerosol instrument manager 10.3.1.0
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Aerosol Instrument Manager 10.3.1.0, supplied by TSI Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/aerosol+instrument+manager+software++release+version+8+0+0+0/med_rxiv__2021__01__26__21250482-53-13-21
Average 90 stars, based on 1 article reviews
aerosol instrument manager 10.3.1.0 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
produxion manager  (Aries Systems Corporation)
90
Aries Systems Corporation produxion manager
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Produxion Manager, supplied by Aries Systems Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/produxion+manager/pmc07992394__giab021_giga___d___20___00244_revision_1-123-5-8
Average 90 stars, based on 1 article reviews
produxion manager - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
nsx® manager  (VMware Inc)
90
VMware Inc nsx® manager
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Nsx® Manager, supplied by VMware Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/nsx++manager/us11689522-138-23-22
Average 90 stars, based on 1 article reviews
nsx® manager - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hypervisor vmware esxi platform  (VMware Inc)
90
VMware Inc hypervisor vmware esxi platform
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Hypervisor Vmware Esxi Platform, supplied by VMware Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/esxi++hypervisor/us11194745-115-25-30
Average 90 stars, based on 1 article reviews
hypervisor vmware esxi platform - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
arcgis version 10.1  (Esri inc)
90
Esri inc arcgis version 10.1
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
Arcgis Version 10.1, supplied by Esri inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/arcgis+10+2/pm26048558-98-24-27
Average 90 stars, based on 1 article reviews
arcgis version 10.1 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
user interface module  (DOE Systems Biology Knowledgebase)
90
DOE Systems Biology Knowledgebase user interface module
(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) <t>ProteOn</t> array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.
User Interface Module, supplied by DOE Systems Biology Knowledgebase, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteon%E2%84%A2+manager+3%2E1%2E0/user+interface+module/us08037009-105-16-40
Average 90 stars, based on 1 article reviews
user interface module - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


(A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) ProteOn array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.

Journal: Cancer immunology research

Article Title: Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA

doi: 10.1158/2326-6066.CIR-19-0023

Figure Lengend Snippet: (A) ELISA demonstrating the binding specificity of 14-25-9 mAb with plate-bound recombinant MBP- and His-tagged hPCNA. His-DJ1 (negative control) and mIgG1 (isotype control). (B) Western blot image demonstrating specific binding of 14-25-9 with His-hPCNA (30kDa) and MBP-hPCNA (71.5kDa) and no binding with His-DJ1. (C) ProteOn array showing the affinity of 14-25-9 at a concentration range of 0–100nM to His-hPCNA. Concentrations represented with lines are, 0nM (Violet, base-line), 6.25nM (Yellow), 25nM (Green), 50nM (Blue), and 100nM (Red). Analysis: bivalent binding model. (D-E) Western blot images showing recognition of endogenous PCNA. Data are representative of three independent experiments. (F) ELISA demonstrating inhibition of NKp44-Ig binding with plate-bound MBP-hPCNA by titrated 14-25-9 and PC10. Percentages of NKp44-Ig binding, were calculated against no-antibody incubation value. Data represents mean±SD of two independent experiments in n=3 biological replicates for each dose. One-way ANOVA was performed among the groups; comparison was done between PC10 and 14-25-9 groups. * p<0.05, **p<0.01, ***p<0.001.

Article Snippet: For the assay, a HTG sensor chip (#1765031) and ProteOn Manager Version 3.1.0.6 (Bio-Rad Laboratories) were employed.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Recombinant, Negative Control, Control, Western Blot, Concentration Assay, Inhibition, Incubation, Comparison